Addiction Care & Empowering the Non-Specialist

The opioid crisis has evolved into a far more complex public health emergency, with synthetic fentanyl and other potent substances like xylazine and kratom now driving overdose deaths. Dr. Benjamin Lai, a family medicine physician at Mayo Clinic, argues that primary care providers—despite not being addiction specialists—are uniquely positioned to lead treatment efforts due to their long-term relationships with patients, greater access, and lower stigma. He emphasizes that substance use disorders are chronic brain conditions rooted in a biopsychosocial-spiritual framework, not moral failings. Contrary to common fears, he asserts that prescribing buprenorphine is no more complicated than managing insulin or warfarin, and that widespread adoption of evidence-based tools like the SBIRT model and telemedicine can bridge gaps in rural and underserved areas. The 2022 CDC guideline revisions and $50 billion in opioid settlement funds are now enabling communities to expand access to treatment. Most importantly, Lai urges clinicians not to overthink the process: start with screening, use available algorithms, and focus on harm reduction and relationship-building. His optimism is grounded in the first documented decline in overdose deaths in 2024 and growing national momentum toward systemic change. The episode dismantles pervasive myths—such as the idea that treating addiction requires specialist-level expertise or that prescribing buprenorphine will flood clinics with patients.